STAT+: Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money
Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No…
Category: biotechnology
STAT+: Milestone Pharma’s nasal spray rapidly restores normal heart rhythm, achieving goal of key study
Milestone Pharmaceuticals said Monday that an experimental nasal-spray medicine acted quickly to treat people experiencing…
.jpg)
STAT+: What to know about Roche’s experimental Alzheimer’s treatment
The next big Alzheimer’s disease study readout is almost here. Roche is nearing the completion…
BIO’s messy transition, mRNA’s future, & Biogen’s next CEO
What’s going on at biotech’s lobbying organization? Where does mRNA go from here? And what…
STAT+: Relmada antidepressant drug fails first of several late-stage clinical trials
Relmada Therapeutics said Thursday that its experimental treatment for depression failed to achieve the primary…
STAT+: Flush with cash from Covid-19 vaccine, BioNTech founders have outsized ambitions
BOSTON — BioNTech CEO Uğur Şahin had been in marathon meetings since he arrived in…
Opinion: Why the U.S. needs a public benefit biopharma industry
The biopharma industry is failing Americans, economically and medically. U.S. biotechnology and pharmaceutical companies, like…
STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate
Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized…
STAT+: Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down
A biotech company co-founded by venture capital firm Atlas Venture has shut down after running…
STAT+: For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune
Last month, word spread that a drug was finally shown to slow Alzheimer’s disease, and…
STAT+: Merck touts positive results on key drug from $11.5 billion Acceleron merger
Merck said Monday the key drug from its $11.5 billion purchase of the biotech Acceleron…
After tough period for lobby, BIO chief Michelle McMurry-Heath goes on leave
WASHINGTON — Michelle McMurry-Heath, one of the most prominent faces of the drug industry in Washington,…
STAT+: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate
A senior researcher who was most recently at Johnson & Johnson has emerged as a…
Listen: Nobels for science, biotech dealmaking, & a friendly FTC
What can we learn from mummy DNA? Is Pfizer single-handedly propping up biotech? And how…
STAT+: CAR-T therapy doesn’t work in all cancer cases. Scientists are starting to figure out why
When CAR-T therapy works against blood cancer, it can work spectacularly, but cancer still returns…
STAT+: The biotech scorecard for the fourth quarter: 13 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option
The Food and Drug Administration approved a new medicine for ALS from Amylyx Pharmaceuticals on…
Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy
Does the latest Alzheimer’s disease drug actually work? When does the FDA call in security?…
STAT+: With rivals on its heels, Illumina launches a new line of high-end DNA sequencers
SAN DIEGO — After a steep drop in its stock price and with mounting competition…
STAT+: Burning questions left unanswered about the latest Alzheimer’s therapy
News of the first clearly successful clinical trial for a new Alzheimer’s disease treatment in…
STAT+: If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes
The announcement Tuesday night from Eisai and Biogen that their experimental medicine, lecanemab, reduced Alzheimer’s…
Virtual Event: When the Barrier to a Breakthrough Drug Is You Can’t Make It
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline…
STAT+: Biotech turns to new and strange viruses to overcome gene therapy’s limitations
CAMBRIDGE, Mass. — The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a…
Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0
When is a pandemic “over?” Did biotech over-SPAC? And what can’t be CRISPR’d? We cover…
Bayer’s venture arm ramps up, seeking to invest $1.3 billion
Over the last six years, a venture capital team run out of pharmaceutical giant Bayer…
STAT+: Researchers show they can quickly turn CAR-T cells on and off, raising hopes for safer cancer treatments
Researchers reported Wednesday that they could quickly and reliably turn CAR-T cells on and off…
STAT+: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
A new CRISPR startup — backed by some big names in venture capital — is…
STAT+: Have researchers hit a wall in the hunt for severe Covid drugs?
It seemed interminably slow then, what with all the haze and fear of fresh plague,…
STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a…
The meth crisis is worse than ever, but new treatments might be around the corner
When it comes to meth addiction, Thomas Robey has long been at a loss. As…
Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred
Is online prescribing a good idea? When is $2 billion not a lot of money?…
Borrowing CAR-T tool from cancer therapy, lupus patients go into remission
Rheumatology — the study of immune-system-driven diseases of the bones, joints, muscles, and in-betweens —…
U.S. to spend more than $2 billion to launch Biden’s biomanufacturing initiative
The federal government is pledging more than $2 billion to launch President Biden’s new national…
.jpg)
STAT+: Medical pioneers team up to launch new cell therapy biotech
Medical pioneers Carl June, Bruce Levine, and Drew Weissman have teamed up to launch a…
STAT+: Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study
Akero Therapeutics said Tuesday that an experimental medicine improved liver scarring at twice the rate…
STAT+: Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments
Clinical trial results reported Monday by Amgen may be enough to confirm the U.S. approval…
STAT+: Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million
In the life sciences industry, where company names derived from “biology” or “genetics” are a…
STAT+: Boston’s most valuable biotech? It’s not who you might expect
The brightest star in Boston’s rapidly growing biotech scene isn’t a flashy new player, but…
Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Is Illumina a victim of its own success? What makes the FDA change its mind?…
STAT+: Data show strong results for Alnylam therapy for heart disease, but magnitude of benefit will stir debate
Detailed data from a successful heart disease study show a therapy developed by Alnylam Pharmaceuticals…
STAT+: In reversal, FDA advisers vote a second time to support approval of Amylyx’s drug for ALS
At the end of an unusual and dramatic meeting on Wednesday, an independent panel of…
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with…
Relay Therapeutics drug shows promise in early trial
A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the…
Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy
Good Therapeutics, a private company that raised just $30 million in venture financing since its…
STAT+: Why Illumina has a merger mess of it own making
For Illumina, the leading maker of DNA sequencing equipment, there was bad news and worse…
STAT+: Illumina wins case against FTC in bid to hold onto early cancer detection company Grail
SAN DIEGO — Sequencing behemoth Illumina on Thursday won its case against the Federal Trade…
Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
What can worms teach us about immortality? How does one become the Godfather? And where…
STAT+: Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight
At the start of 2021, blue-chip biotech investor ARCH Venture Partners and a relatively unknown…
STAT+: For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career
In the history of the global pharmaceutical industry, there have been many big thinkers, brash…